Vimian Group (VIMIAN) Q3 2024 earnings summary

Executive summary

• Achieved 10% organic revenue growth and margin expansion in Q3 2024, with strong adjusted EBITDA/EBITA growth and improved operational cash flow.

• Entered the veterinary dental MedTech niche through the acquisition of iM3, a global leader in the space.

• Net profit for the quarter was EUR -1.9 million, impacted by high comparability items and negative FX effects.

• Cash flow from operating activities improved to EUR 16.7 million in Q3.

Financial highlights

• Q3 revenue was EUR 87.6 million, up 10% year-over-year, driven by Specialty Pharma, MedTech, and Veterinary Services.

• Adjusted EBITDA/EBITA grew 20% to EUR 21.9 million, with margin improving to 25% (up from 22.9%).

• Operating profit (EBIT) was EUR 10.1 million, up 2% year-over-year, impacted by EUR 6.5 million in items affecting comparability.

• Net profit for the quarter was EUR -1.9 million, down from EUR 7.6 million, due to one-time costs and FX impacts.

• Cash flow from operating activities improved to EUR 16.7 million; net working capital reduced to EUR 80.8 million (23% of revenue).

Outlook and guidance

• Near-term priorities include organic growth, operational improvements, onboarding iM3, and advancing the M&A pipeline.

• U.S. MedTech market remains soft, especially in elective surgeries; monitoring for potential recovery.

• Diagnostics margins expected to gradually improve as companion animal solutions gain traction, but single-digit margins likely for a few more quarters.

• Long-term industry growth drivers remain strong, including pet humanization and aging pet population.